QUINCE THERAPEUTICS INC (QNCX) Stock Price & Overview

NASDAQ:QNCXUS22053A1079

Current stock price

1.34 USD
+0.07 (+5.51%)
At close:
1.3306 USD
-0.01 (-0.7%)
After Hours:

The current stock price of QNCX is 1.34 USD. Today QNCX is up by 5.51%. In the past month the price increased by 31.89%. In the past year, price decreased by -89.11%.

QNCX Key Statistics

52-Week Range0.8 - 45.499
Current QNCX stock price positioned within its 52-week range.
1-Month Range0.845 - 3.843
Current QNCX stock price positioned within its 1-month range.
Market Cap
21.842M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-15.30
Dividend Yield
N/A

QNCX Stock Performance

Today
+5.51%
1 Week
+7.20%
1 Month
+31.89%
3 Months
-95.65%
Longer-term
6 Months -92.39%
1 Year -89.11%
2 Years -87.48%
3 Years -91.24%
5 Years N/A
10 Years N/A

QNCX Stock Chart

QUINCE THERAPEUTICS INC / QNCX Daily stock chart

QNCX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to QNCX. When comparing the yearly performance of all stocks, QNCX is a bad performer in the overall market: 99.63% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

QNCX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to QNCX. The financial health of QNCX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

QNCX Earnings

Next Earnings DateMay 11, 2026
Last Earnings DateApr 10, 2026
PeriodQ4 / 2025
EPS Reported-$7.10
Revenue Reported
EPS Surprise -268.69%
Revenue Surprise %

QNCX Forecast & Estimates


Analysts
Analysts46.67
Price TargetN/A
EPS Next Y93.23%
Revenue Next YearN/A

QNCX Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

QNCX Financial Highlights

Over the last trailing twelve months QNCX reported a non-GAAP Earnings per Share(EPS) of -15.3.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-56.98M
Industry RankSector Rank
PM (TTM) N/A
ROA -51.85%
ROE -5380.45%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-153.57%
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

QNCX Ownership

Ownership
Inst Owners37.8%
Shares16.30M
Float15.78M
Ins Owners9.28%
Short Float %N/A
Short Ratio0.11

About QNCX

Company Profile

QNCX logo image Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. The company is headquartered in South San Francisco, California and currently employs 36 full-time employees. The company went IPO on 2019-05-09. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.

Company Info

IPO: 2019-05-09

QUINCE THERAPEUTICS INC

601 Gateway Boulevard, Suite 1250

South San Francisco CALIFORNIA US

Employees: 36

QNCX Company Website

QNCX Investor Relations

Phone: 14159105717

QUINCE THERAPEUTICS INC / QNCX FAQ

Can you describe the business of QUINCE THERAPEUTICS INC?

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. The company is headquartered in South San Francisco, California and currently employs 36 full-time employees. The company went IPO on 2019-05-09. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.


Can you provide the latest stock price for QUINCE THERAPEUTICS INC?

The current stock price of QNCX is 1.34 USD. The price increased by 5.51% in the last trading session.


Does QUINCE THERAPEUTICS INC pay dividends?

QNCX does not pay a dividend.


How is the ChartMill rating for QUINCE THERAPEUTICS INC?

QNCX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Should I buy QNCX stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on QNCX.


Can you provide the market cap for QUINCE THERAPEUTICS INC?

QUINCE THERAPEUTICS INC (QNCX) has a market capitalization of 21.84M USD. This makes QNCX a Nano Cap stock.


What is the ownership structure of QUINCE THERAPEUTICS INC (QNCX)?

You can find the ownership structure of QUINCE THERAPEUTICS INC (QNCX) on the Ownership tab.